deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT03195699

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients with Advanced Cancers

Sponsor: M.D. Anderson Cancer Center

Conditions Advanced Cancer Breast Cancer Colorectal Cancer Gastric Adenocarcinoma Head and Neck Squamous Cell Carcinoma Hepatocellular Cancer Melanoma Non Small Cell Lung Cancer
Interventions TTI-101
Updated 23 times since 2017 Last updated: Mar 18, 2025 Started: Nov 15, 2017 Primary completion: Jun 24, 2024 Completion: Jun 24, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Cancer and Breast Cancer and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Feb 2020 · 16 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Dec 2020 · 9 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Nov 2022 · 4 months · monthly snapshot~Nov 2022 – ~Dec 2023 · 13 months · monthly snapshot~Dec 2023 – ~May 2024 · 5 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 17 months · monthly snapshot

Change History

23 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 18 earlier versions

  1. Nov 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Jul 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  3. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  4. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE1

  5. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  6. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  8. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  9. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  10. Mar 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  11. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE1

  12. Oct 2018 — Feb 2020 [monthly]

    Recruiting PHASE1

  13. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  14. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  15. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  16. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  17. Oct 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE1

  18. Aug 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • Tvardi Therapeutics, Incorporated
Data source: Tvardi Therapeutics, Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations